Summary of Significant Accounting Policies - Revenue Recognition, PPE, Licensing and Research (Details)			1 Months Ended	12 Months Ended
	Dec. 31, 2016 USD ($)	Oct. 02, 2014	Oct. 31, 2014 USD ($)	Dec. 31, 2019 USD ($) agreement	Dec. 31, 2018 USD ($)
Accounting Policies [Abstract]
Number of distribution and license agreements | agreement				2
Customers average payment term				30 days
Distributors average payment term				45 days
Summary of significant accounting policies
Net Revenue				$ 61,302,801	$ 63,388,617
Impairment losses				0	0
Bad-debt expense				0	0
Contract assets				0	0
Revenue performance obligation				12,100,000	14,300,000
Impairments of long-lived assets				$ 0	0
Finite-lived intangible asset useful life				17 years
Contract liabilities				$ 12,076,000	14,329,000
Research and product development expense				6,886,251	5,642,317
Product license agreement expense				$ 0	1,100,000
Minimum
Summary of significant accounting policies
Property and equipment useful life				3 years
Market and performance-based stock unit awards service period				1 year
Maximum
Summary of significant accounting policies
Property and equipment useful life				10 years
Market and performance-based stock unit awards service period				2 years
Product license agreement
Summary of significant accounting policies
Product license agreement expense					1,100,000
Wanbang Biopharmaceutical
Summary of significant accounting policies
Upfront payment	$ 4,000,000
Deferred drug license revenue				$ 300,000	300,000
Contract liabilities				2,900,000	3,200,000
Baxter
Summary of significant accounting policies
Revenue performance obligation				9,100,000
Distribution agreement term		10 years
Upfront payment			$ 20,000,000
Deferred drug license revenue				2,100,000	2,100,000
Contract liabilities				$ 9,100,000	11,100,000
Upfront payment benefit percent				25.00%
License
Summary of significant accounting policies
Net Revenue				$ 2,300,000	2,400,000
Product
Summary of significant accounting policies
Net Revenue				59,000,000	61,000,000
Concentrate Products
Summary of significant accounting policies
Net Revenue				60,758,000	63,116,000
Reserve for returns				$ 0	$ 0
Baxter Healthcare Organization
Summary of significant accounting policies
Distribution agreement term			10 years